Sunarium Sunitinib Malate Capsules 50 mg is a prescription oncology medicine identified as containing Sunitinib Malate equivalent to Sunitinib 50 mg per capsule, subject to confirmation from the approved product label.

Sunitinib is an oral multikinase inhibitor used as targeted anticancer therapy.

It inhibits several receptor tyrosine kinases involved in tumor-cell signaling, angiogenesis and tumor growth.

Sunitinib is an established treatment option in selected settings involving advanced renal cell carcinoma, gastrointestinal stromal tumors and progressive pancreatic neuroendocrine tumors.

The suitability of sunitinib depends on the cancer diagnosis, stage, previous treatment, patient condition and applicable regulatory approvals.

The stated 50 mg capsule strength does not represent a universal patient dose.

The exact manufacturer, capsule composition, packaging and approved indications of Sunarium must be verified from its approved Indian product documentation.

Marketed by Essentials Emporium Enterprises, Sunarium is listed within the oncology pharmaceutical category for hospitals, cancer treatment centres and authorized pharmaceutical buyers.

Key Product Features